Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7009 with peginterferon alfa-2a and ribavirin in treatment-naive chronic hepatitis C genotype 1
2008-000149-72Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in hepatitis C virus infection comparing MK-7009 + peginterferon alfa-2a + ribavirin with Placebo + peginterferon alfa-2a + ribavirin (2 arms). Primary endpoint: Rapid viral response at Week 4. Started Apr 2008; status: completed.
02
Drugs
vaniprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2008-000149-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000149-72.